1251832-23-1Relevant articles and documents
The First Synthesis and Iron Binding Studies of the Natural Product, myo-Inositol 1,2,3-Trisphosphate
Spiers, Ian D.,Freeman, Sally,Poyner, David R.,Schwalbe, Carl H.
, p. 2125 - 2128 (1995)
The natural product myo-inositol 1,2,3-trisphosphate 1 has been prepared and shown to inhibit Fe3+-catalysed hydroxyl radical formation.
A new efficient method for resolution of myo-inositol derivatives by enzyme catalyzed regio- and enantio-selective esterification in organic solvent
Ling,Watanabe,Akiyama,Ozaki
, p. 1911 - 1914 (1992)
Racemic 1,2:5,6-di-O-cyclohexylidene- and 1,2:3,4-di-O-cyclohexylidene-myo-inositol were resolved by enzyme catalyzed esterification in organic solvent.
ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
-
Page/Page column 34, (2019/11/12)
The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.
H2SO4-silica: An eco-friendly heterogeneous catalyst for the differential protection of myo-inositol hydroxyl groups
Vibhute, Amol M.,Sureshan, Kana M.
, p. 7321 - 7329 (2013/07/05)
There is enormous interest in myo-inositol derivatives as they serve as precursors for the synthesis of several biologically important phosphoinositols, natural products, catalyst, supramolecular architectures etc. However the presence of six secondary hy